Latest Regulatory Affairs News

Page 1 of 32
Miro Sciences says Australia’s medicines regulator has completed its inspection of the manufacturing site for StemSmart, supporting the company’s planned Phase 2 Crohn’s disease trial. The inspection is a significant readiness step, but it is not itself approval to begin the study or confirmation of a successful audit outcome.
Ada Torres
Ada Torres
12 Nov 2026
Amgen delivered 8% third-quarter revenue growth and a 19% increase in GAAP diluted EPS, while newer medicines continued to expand. The result came alongside sharp declines in Prolia and XGEVA sales from biosimilar competition and a busy pipeline of late-stage programmes.
Victor Sage
Victor Sage
4 Nov 2026
Vectus Biosystems has secured FDA acceptance of a pre-IND Type B meeting for VB0004, a key regulatory step for its idiopathic pulmonary fibrosis programme. The biotech ended September with $410,000 in cash and reported estimated funding for just 1.33 quarters of operations.
Ada Torres
Ada Torres
29 Oct 2026
AdAlta expects an additional R&D Tax Incentive refund of more than A$1 million after securing approval for specified overseas work on its EW-001 CAR-T therapy. The cash benefit arrives as the company prepares for a US FDA pre-IND meeting in November.
Ada Torres
Ada Torres
19 Oct 2026
ANO says Australian revenue from its Veganic sunscreen products fell 71% in the first quarter of FY27 after customer cancellations linked to media coverage and TGA involvement over product labelling. The company is preparing a legal claim against MooGoo, but no proceedings have yet been filed and the potential amount remains undisclosed.
Victor Sage
Victor Sage
8 Oct 2026
Aspermont has acknowledged that a director’s initial interest notice was lodged around eight months late, after ASX raised possible breaches of its disclosure rules. The company blamed an administrative oversight and said it will tighten appointment procedures, but no penalty or formal breach finding was disclosed.
Victor Sage
Victor Sage
8 Oct 2026
Optiscan Imaging has lodged a 510(k) submission for its InForm digital pathology device, moving the product from development into formal US regulatory assessment. FDA clearance is not assured, but a successful determination could open the door to commercial distribution in the company’s target market.
Victor Sage
Victor Sage
1 Oct 2026
Clarity Pharmaceuticals is approaching pivotal Phase III readouts for its prostate cancer imaging agent, backed by AUD178.3 million in liquid assets. The radiopharmaceutical developer remains deeply loss-making, but expanded manufacturing capacity and early clinical signals are pulling its commercial ambitions into sharper focus.
Victor Sage
Victor Sage
30 Sept 2026
A2MP Investments has issued a third supplementary bidder's statement disputing the valuation and assumptions underpinning Canyon Resources' takeover response, highlighting persistent funding uncertainties and project execution risks. The bidder insists its offer remains the sole liquidity option for shareholders ahead of the September 21 deadline.
Maxwell Dee
Maxwell Dee
2 Sept 2026
Actinogen Medical has locked in full underwriting for nearly 127 million unlisted options, guaranteeing $4.77 million in fresh funding as it approaches pivotal Alzheimer’s trial results due in November.
Ada Torres
Ada Torres
1 Sept 2026
The Star Entertainment Group narrowed its net loss to $307 million in FY26, boosted by refinancing, operational improvements, and a joint venture exit, while navigating ongoing regulatory scrutiny and remediation efforts.
Victor Sage
Victor Sage
31 Aug 2026
Avecho has resumed enrolment for the last stage of its pivotal Phase III trial of a TPM®-enhanced CBD capsule for insomnia, following a unanimous Data Monitoring Board recommendation to continue without expanding the sample size.
Ada Torres
Ada Torres
31 Aug 2026

Browse the archive

Full archive